Dual antithrombotic therapy combined with the blood thinner dabigatran and a P2Y inhibitor could be a more effective—and less risky—alternative to standard care in atrial fibrillation (AFib) patients undergoing percutaneous coronary intervention (PCI), a study published this month in the New England Journal of Medicine reports.

Abbott has received FDA clearance for its smartphone-compatible insertable cardiac monitor (ICM), the healthcare company announced Oct. 23. The device allows a patient to actively monitor his heart activity while giving physicians the ability to identify arrhythmias remotely.

Higher levels of thyroid hormone in the blood were associated with an increased risk of atrial fibrillation (AFib), even when the levels were within normal range, according to an analysis of 11 studies containing more than 30,000 people.

Icelandic researchers have uncovered two novel genetic variants of atrial fibrillation (AFib), one of which could increase the risk of developing AFib for susceptible patients.

GLEN MILLS, Pa., Oct. 17, 2017 — Unequal®, a leading manufacturer of sports protective gear, announced that the Food and Drug Administration has determined that Unequal's patented HART® CC Pad device, found in every Unequal HART chest protector, can improve safety on the playing field.

A large-scale study of nearly 80,000 patients suggests men develop atrial fibrillation (AFib) an average of 10 years earlier than women, according to researched from the American Heart Association.

Heart experts have launched a pair of smartphone and tablet applications designed to treat atrial fibrillation (AFib), the most common cardiac rhythm disorder.

Patients with Brugada syndrome (BrS) benefit from implantable cardioverter defibrillators (ICDs) but are at significant risk of device-related complications, according to the longest-term study to date on the topic.